title: The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation.
abstract: BACKGROUND
  Graft-versus-host disease (GVHD) remains the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Steroids along with calcineurin inhibitors remain the standard initial therapy, however, less than half of the patients completely respond and there is no uniformly accepted therapy for patients with steroid-resistant GVHD.
  
  
  METHODS
  This paper reviews the current role and ongoing development of mAbs in the treatment of GVHD. Various mAbs to cell surface antigens on GVHD effector cells have been investigated for the treatment of acute GVHD: these include anti-TNF-α antibodies, IL-2 receptor antagonists, anti-CD3 and anti-CD52 mAbs, while anti-CD20 mAb has been extensively investigated in the setting of chronic GVHD. Overall, response rates have been reported to be greater than 60%, although it should be emphasized that the long-term survival still remains suboptimal, mainly due to the detrimental side effects of infectious complications, progressive GVHD and relapse of underlying malignancy.
  
  
  CONCLUSIONS
  Future challenges will include more appropriate definition of these agents in the therapeutic scenario of GVHD. Combinations of mAbs or mAb combined with newer immunosuppressive drugs might potentially achieve greater success, especially if used early in the disease process.
authors.affiliation: Stem Cell Transplant Unit, AOU San Giovanni Battista, Corso Bramante 88, 10126 Turin, Italy. abusca@molinette.piemonte.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Busca
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal